Antibodies for Prostate Cancer Research

Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous cancer among men and continues to pose a major clinical challenge for diagnosis and treatment.
By: GeneTex
 
July 8, 2015 - PRLog -- . Because of the widespread use of Prostate-Specific Antigen (PSA) testing, diagnosis of PCa in patients with a low Gleason score (and thus a predicted less aggressive tumor) has vastly increased, leading to an overtreatment of patients who would otherwise require only conservative management. As a result, the impact of treatment on PCa survival is relatively small. Despite immense efforts to better understand the molecular mechanisms underlying prostate carcinogenesis, further research is necessary to discover biomarkers that will be able to distinguish between indolent and aggressive forms of PCa, which will then help to maximize the benefits of treatment.

GeneTex proudly offers a large selection of high-quality antibodies for prostate cancer research. Our panel of highly specific and sensitive reagents includes antibodies against the Androgen Receptor (AR), ERG, EZH2, GSTP1, Kallikreins, Prostate-Specific Antigen (PSA) and PTEN, the majority of which are validated for multiple applications.

Please see our highlighted products below, or click the button for our complete catalog of PCa antibodies.

http://www.genetex.com/Web/News/Antibodies-for-Prostate-C...

Contact
GeneTex, Inc.
***@genetex.com
End
Source:GeneTex
Email:***@genetex.com Email Verified
Tags:Prostate, Cancer, Research, Antibody
Industry:Biotech, Science
Location:United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
GeneTex, Inc. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share